SOPHiA GENETICS SA (SOPH) chair logs 8,500-share open-market sale

Rhea-AI Filing Summary

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 8,500 Ordinary Shares on July 10, 2026 at a weighted average price of $5.6225 per share. The transaction was made pursuant to a Rule 10b5-1(c) trading plan, and he continues to hold 3,532,622 shares directly. The shares were sold in multiple trades at prices between $5.53 and $5.77.

Insider Trade Summary 10b5-1

Net Seller: 8,500 shares ($47,791)

Net Sell 1 txn

Insider Camblong Jurgi

Role Executive Chairman

Sold 8,500 shs ($48K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	8,500	$5.6225	$48K

Holdings After Transaction: Ordinary Shares — 3,532,622 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.53 to $5.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 8,500 shares Weighted average sale price: $5.6225 per share Post-transaction holdings: 3,532,622 shares +1 more

4 metrics

Shares sold 8,500 shares Ordinary Shares sold in open-market transaction on July 10, 2026

Weighted average sale price $5.6225 per share Average price for the 8,500 Ordinary Shares sold

Post-transaction holdings 3,532,622 shares Ordinary Shares directly held by Jurgi Camblong after the sale

Sale price range $5.53 to $5.77 per share Range of prices for multiple trades included in the reported sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale market

"transaction_action: open-market sale of 8,500 Ordinary Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title: Ordinary Shares of SOPHiA GENETICS SA"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/14/2026 - 04:03 PM Accepted by SEC EDGAR 07/14/2026 - 04:02 PM Learn about SEC filing dates

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Jurgi Camblong?

SOPHiA GENETICS reported that Executive Chairman Jurgi Camblong sold 8,500 Ordinary Shares in an open-market transaction. The trade occurred on July 10, 2026 at a weighted average price of $5.6225 per share, as disclosed in a Form 4 filing.

How many SOPHiA GENETICS (SOPH) shares did Jurgi Camblong sell and at what price?

Jurgi Camblong sold 8,500 Ordinary Shares of SOPHiA GENETICS at a weighted average price of $5.6225 per share. According to the disclosure, the shares were sold in multiple trades at prices ranging from $5.53 to $5.77, inclusive.

When did the SOPHiA GENETICS (SOPH) Executive Chairman’s share sale take place?

The Executive Chairman’s share sale took place on July 10, 2026. On that date, Jurgi Camblong executed an open-market sale of 8,500 Ordinary Shares of SOPHiA GENETICS at a weighted average price of $5.6225 per share, as reported.

Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a duly adopted trading plan under Rule 10b5-1(c). This indicates the 8,500-share sale by Executive Chairman Jurgi Camblong was pre-arranged rather than discretionary market timing.

How many SOPHiA GENETICS (SOPH) shares does Jurgi Camblong hold after the sale?

After the reported transaction, Jurgi Camblong directly holds 3,532,622 Ordinary Shares of SOPHiA GENETICS. This post-transaction holding reflects his remaining direct ownership following the 8,500-share open-market sale disclosed in the Form 4.

What price range applied to the SOPHiA GENETICS (SOPH) insider share sales?

The filing notes that the shares were sold at prices ranging from $5.53 to $5.77, inclusive. The reported transaction price of $5.6225 per share represents a weighted average across these multiple open-market trades executed on July 10, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/10/2026		S		8,500(1)	D	$5.6225(2)	3,532,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.53 to $5.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)